Aetiology of severe aplastic anaemia and outcome after allogeneic bone marrow transplantation or immunosuppression therapy. Working Party on Severe Aplastic Anaemia of the European Blood and Marrow Transplantation Group.
This study is based on 2163 patients with severe aplastic anaemia from the European Bone Marrow Transplantation Working Party Registry on Severe Aplastic Anaemia. It was designed to define patients' characteristics according to different aetiology and to assess the impact of aetiology of the aplasia on treatment outcome. Significant differences were found in age, sex, disease severity and DR typing between idiopathic, post-hepatitis and drug-associated severe aplastic anaemia. These differences did not affect the overall outcome of patients treated with bone marrow transplantation (BMT) or immunosuppression (IS) therapy.
Bacigalupo
A
A
Divisione Ematologia 2, Ospedale San Martino, Genova, Italy.
D000293:Adolescent; D000328:Adult; D000741:Anemia, Aplastic / Q000209:etiology* / Q000628:therapy; D016026:Bone Marrow Transplantation; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007165:Immunosuppression Therapy; D008297:Male; D008875:Middle Aged; D012042:Registries; D014184:Transplantation, Homologous; D016896:Treatment Outcome